{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:53:41Z","timestamp":1781276021126,"version":"3.54.1"},"reference-count":61,"publisher":"Oncology Nursing Society (ONS)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ONF"],"published-print":{"date-parts":[[2020,9,1]]},"DOI":"10.1188\/20.onf.e149-e160","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T08:19:01Z","timestamp":1598257141000},"page":"E149-E160","source":"Crossref","is-referenced-by-count":10,"title":["Targeted Therapy\u2013 and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis"],"prefix":"10.1188","volume":"47","author":[{"given":"Jingyi","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdoleen","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Nayfeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Malandris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Manolopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Ginex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Dunnack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Abd-Rabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moutie","family":"Rajjoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Prokop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hassan","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1302","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Arrieta, O., Vega-Gonz\u00e1lez, M.T., L\u00f3pez-Mac\u00edas, D., Mart\u00ednez-Hern\u00e1ndez, J.N., Bacon-Fonseca, L., Macedo-P\u00e9rez, E.O., . . . de la Garza-Salazar, J. (2015). Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib-induced skin toxicities in non-small cell lung cancer patients. Lung Cancer, 88(3), 282\u2013288. https:\/\/doi.org\/10.1016\/j.lungcan.2015.03.019","DOI":"10.1016\/j.lungcan.2015.03.019"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Betticher, D.C., Delmore, G., Breitenstein, U., Anchisi, S., Zimmerli-Schwab, B., M\u00fcller, A., . . . Trueb, R.R. (2013). Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Supportive Care in Cancer, 21(9), 2565\u20132573. https:\/\/doi.org\/10.1007\/s00520-013-1804-9","DOI":"10.1007\/s00520-013-1804-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Braik, T., Yim, B., Evans, A., Kassem, M., Mullane, M., Lad, T., . . . McDunn, S. (2014). Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy. Journal of Community and Supportive Oncology, 12(2), 65\u201370. https:\/\/doi.org\/10.12788\/jcso.0017","DOI":"10.12788\/jcso.0017"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Brant, J.M., Wilkes, G.M., & Doyle, D. (2005). Palmar-plantar erythrodysesthesia. Clinical Journal of Oncology Nursing, 9(1), 103\u2013106. https:\/\/doi.org\/10.1188\/05.CJON.103-106.","DOI":"10.1188\/05.CJON.103-106"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Chalermchai, T., Tantiphlachiva, K., Suwanrusme, H., Voravud, N., & Sriuranpong, V. (2010). Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. Asia-Pacific Journal of Clinical Oncology, 6(3), 155\u2013160. https:\/\/doi.org\/10.1111\/j.1743-7563.2010.01311.x","DOI":"10.1111\/j.1743-7563.2010.01311.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Coleman, S., Kovtun, I., Nguyen, P.L., Pittelkow, M., & Jatoi, A. (2010). A qualitative study of the ramifications of rash from epidermal growth factor receptor (EGFR) inhibitors. Psycho-Oncology, 20(11), 1246\u20131249. https:\/\/doi.org\/10.1002\/pon.1847","DOI":"10.1002\/pon.1847"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Corrie, P.G., Bulusu, R., Wilson, C.B., Armstrong, G., Bond, S., Hardy, R., . . . Osborne, M. (2012). A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. British Journal of Cancer, 107(4), 585\u2013587. https:\/\/doi.org\/10.1038\/bjc.2012.318","DOI":"10.1038\/bjc.2012.318"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Deplanque, G., Gervais, R., Vergnenegre, A., Falchero, L., Souquet, P.J., Chavaillon, J.M., . . . Chosidow, O. (2016). Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. Journal of the American Academy of Dermatology, 74(6), 1077\u20131085. https:\/\/doi.org\/10.1016\/j.jaad.2016.01.019","DOI":"10.1016\/j.jaad.2016.01.019"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Gressett, S.M., Stanford, B.L., & Hardwicke, F. (2006). Management of hand-foot syndrome induced by capecitabine. Journal of Oncology Pharmacy Practice, 12(3), 131\u2013141. https:\/\/doi.org\/10.1177\/1078155206069242","DOI":"10.1177\/1078155206069242"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Gomez, P., & Lacouture, M.E. (2011). Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: Experience in breast cancer. Oncologist, 16(11), 1508\u20131519. https:\/\/doi.org\/10.1634\/theoncologist.2011-0115","DOI":"10.1634\/theoncologist.2011-0115"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Guyatt, G., Oxman, A.D., Akl, E.A., Kunz, R., Vist, G., Brozek, J., . . . deBeer, H. (2011). GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology, 64(4), 383\u2013394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Guyatt, G.H., Oxman, A.D., Kunz, R., Atkins, D., Brozek, J., Vist, G., . . . Sch\u00fcnemann, H.J. (2011). GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology, 64(4), 395\u2013400. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.09.012","DOI":"10.1016\/j.jclinepi.2010.09.012"},{"key":"13","unstructured":"Higgins, J., & Green, S. (Eds.) (2011). Cochrane handbook for systematic reviews of interventions [v.5.1.0]. https:\/\/handbook-5-1.cochrane.org"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T. (2003). Measuring inconsistency in meta-analyses. BMJ, 327(7414), 557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","DOI":"10.1136\/bmj.327.7414.557"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Hofheinz, R.D., Lorenzen, S., Trojan, J., Ocvirk, J., Ettrich, T.J., Al-Batran, S.E., . . . Merx, K. (2018). EVITA\u2014A double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. Annals of Oncology, 29(4), 1010\u20131015. https:\/\/doi.org\/10.1093\/annonc\/mdy015","DOI":"10.1093\/annonc\/mdy015"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Hoesly, F.J., Baker, S.G., Gunawardane, N.D., & Cotliar, J.A. (2011). Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: Case report and review of the literature. Archives of Dermatology, 147(12), 1418\u20131423. https:\/\/doi.org\/10.1001\/archdermatol.2011.320","DOI":"10.1001\/archdermatol.2011.320"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Jatoi, A., Dakhil, S.R., Sloan, J.A., Kugler, J.W., Rowland, K.M., Jr., Schaefer, P.L., . . . Loprinzi, C.L. (2011). Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: Results from the North Central Cancer Treatment Group (Supplementary N03CB). Supportive Care in Cancer, 19(10), 1601\u20131607. https:\/\/doi.org\/10.1007\/s00520-010-0988-5","DOI":"10.1007\/s00520-010-0988-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Jatoi, A., Rowland, K., Sloan, J.A., Gross, H.M., Fishkin, P.A., Kahanic, S.P., . . . Loprinzi, C.L. (2008). Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer, 113(4), 847\u2013853. https:\/\/doi.org\/10.1002\/cncr.23621","DOI":"10.1002\/cncr.23621"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Kang, Y.K., Lee, S.S., Yoon, D.H., Lee, S.Y., Chun, Y.J., Kim, M.S., . . . Kim, T.W. (2010). Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: Results of a randomized, double-blind, placebo-controlled study. Journal of Clinical Oncology, 28(24), 3824\u20133829. https:\/\/doi.org\/10.1200\/jco.2010.29.1807","DOI":"10.1200\/JCO.2010.29.1807"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Kargar, M., Sarvestani, R.S., Khojasteh, H.N., & Heidari, M.T. (2011). Efficacy of penguin cap as scalp cooling system for prevention of alopecia in patients undergoing chemotherapy. Journal of Advanced Nursing, 67(11), 2473\u20132477. https:\/\/doi.org\/10.1111\/j.1365-2648.2011.05668.x","DOI":"10.1111\/j.1365-2648.2011.05668.x"},{"key":"21","unstructured":"Lacouture, M.E. (2009). The growing importance of skin toxicity in EGFR inhibitor therapy. Oncology, 23(2), 194\u2013194."},{"key":"22","doi-asserted-by":"crossref","unstructured":"Lacouture, M.E., Anadkat, M., Jatoi, A., Garawin, T., Bohac, C., & Mitchell, E. (2018). Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: A systematic review. Clinical Colorectal Cancer, 17(2), 85\u201396. https:\/\/doi.org\/10.1016\/j.clcc.2017.12.004","DOI":"10.1016\/j.clcc.2017.12.004"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Lacouture, M.E., Keefe, D.M., Sonis, S., Jatoi, A., Gernhardt, D., Wang, T., . . . Garon, E.B. (2016). A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Annals of Oncology, 27(9), 1712\u20131718. https:\/\/doi.org\/10.1093\/annonc\/mdw227","DOI":"10.1093\/annonc\/mdw227"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Lacouture, M.E., & Lai, S.E. (2006). The PRIDE (papulopustules and\/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. British Journal of Dermatology, 155(4), 852\u2013854. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07452.x","DOI":"10.1111\/j.1365-2133.2006.07452.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Lacouture, M.E., Mitchell, E.P., Piperdi, B., Pillai, M.V., Shearer, H., Iannotti, N., . . . Yassine, M. (2010). Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 28(8), 1351\u20131357. https:\/\/doi.org\/10.1200\/JCO.2008.21.7828","DOI":"10.1200\/JCO.2008.21.7828"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Lacouture, M.E., Reilly, L.M., Gerami, P., & Guitart, J. (2008). Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Annals of Oncology, 19(11), 1955\u20131961. https:\/\/doi.org\/10.1093\/annonc\/mdn389","DOI":"10.1093\/annonc\/mdn389"},{"key":"27","unstructured":"Li, A.M., Miao, J.H., Liu, H., Ma, Y.Z., & Sun, Z.C. (2015). Drug-induced skin toxicity and clinical nursing of VitK cream on colorectal cancer patients. Pakistan Journal of Pharmaceutical Sciences, 28(4, Suppl.), 1499\u20131503."},{"key":"28","doi-asserted-by":"crossref","unstructured":"Lin, S.M., Lu, S.N., Chen, P.T., Jeng, L.B., Chen, S.C., Hu, C.T., . . . Meinhardt, G. (2017). HATT: A phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. Hepatology International, 11(2), 199\u2013208. https:\/\/doi.org\/10.1007\/s12072-016-9774-x","DOI":"10.1007\/s12072-016-9774-x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Lipworth, A.D., Robert, C., & Zhu, A.X. (2009). Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): Focus on sorafenib and sunitinib. Oncology, 77(5), 257\u2013271. https:\/\/doi.org\/10.1159\/000258880","DOI":"10.1159\/000258880"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Lorusso, D., Di Stefano, A., Carone, V., Fagotti, A., Pisconti, S., & Scambia, G. (2007). Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (\u2018hand-foot\u2019 syndrome). Annals of Oncology, 18(7), 1159\u20131164. https:\/\/doi.org\/10.1093\/annonc\/mdl477","DOI":"10.1093\/annonc\/mdl477"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Lucchini, E., Pilotto, S., Spada, E., Melisi, D., Bria, E., & Tortora, G. (2014). Targeting the epidermal growth factor receptor in solid tumors: Focus on safety. Expert Opinion on Drug Safety, 13(5), 535\u2013549. https:\/\/doi.org\/10.1517\/14740338.2014.904283","DOI":"10.1517\/14740338.2014.904283"},{"key":"32","doi-asserted-by":"crossref","unstructured":"McLellan, B., Ciardiello, F., Lacouture, M.E., Segaert, S., & Van Cutsem, E. (2015). Regorafenib-associated hand\u2013foot skin reaction: Practical advice on diagnosis, prevention, and management. Annals of Oncology, 26(10), 2017\u20132026. https:\/\/doi.org\/10.1093\/annonc\/mdv244","DOI":"10.1093\/annonc\/mdv244"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Melosky, B., Anderson, H., Burkes, R.L., Chu, Q., Hao, D., Ho, V., . . . Laskin, J.J. (2016). Pan Canadian rash trial: A randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancer. Journal of Clinical Oncology, 34(8), 810\u2013815. https:\/\/doi.org\/10.1200\/jco.2015.62.3918","DOI":"10.1200\/JCO.2015.62.3918"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., & Altman, D.G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLOS Medicine, 6(7), e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","DOI":"10.1371\/journal.pmed.1000097"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Mortimer, J.E., Lauman, M.K., Tan, B., Dempsey, C.L., Shillington, A.C., & Hutchins, K.S. (2003). Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine. Journal of Oncology Pharmacy Practice, 9(4), 161\u2013166. https:\/\/doi.org\/10.1191\/1078155203jp116oa","DOI":"10.1191\/1078155203jp116oa"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Nangia, J., Wang, T., Osborne, C., Niravath, P., Otte, K., Papish, S., . . . Rimawi, M. (2017). Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: The SCALP randomized clinical trial. JAMA, 317(6), 596\u2013605. https:\/\/doi.org\/10.1001\/jama.2016.20939","DOI":"10.1001\/jama.2016.20939"},{"key":"37","unstructured":"Nardone, B., Hensley, J.R., Kulik, L., West, D.P., Mulcahy, M., Rademaker, A., & Lacouture, M.E. (2012). The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. Journal of Drugs in Dermatology, 11(11), e61\u2013e65."},{"key":"38","doi-asserted-by":"crossref","unstructured":"Ocvirk, J., & Cencelj, S. (2010). Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. Journal of the European Academy of Dermatology and Venereology, 24(4), 453\u2013459. https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03446.x","DOI":"10.1111\/j.1468-3083.2009.03446.x"},{"key":"39","unstructured":"Ota, M., Tatsumi, K., Suwa, H., Watanabe, J., Watanabe, K., Osada, S., . . . Endo, I. (2014). The effect of pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study. Hepato-Gastroenterology, 61(132), 1008\u20131013."},{"key":"40","doi-asserted-by":"crossref","unstructured":"Proti\u00e8re, C., Evans, K., Camerlo, J., d\u2019Ingrado, M.P., Macquart-Moulin, G., Viens, P., . . . Genre, D. (2002). Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy. Supportive Care in Cancer, 10(7), 529\u2013537. https:\/\/doi.org\/10.1007\/s00520-002-0375-y","DOI":"10.1007\/s00520-002-0375-y"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Ren, Z., Zhu, K., Kang, H., Lu, M., Qu, Z., Lu, L., . . . Ye, S.L. (2015). Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology, 33(8), 894\u2013900. https:\/\/doi.org\/10.1200\/jco.2013.52.9651","DOI":"10.1200\/JCO.2013.52.9651"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Roe, H. (2014). Scalp cooling: Management option for chemotherapy-induced alopecia. British Journal of Nursing, 23(Suppl. 16), S4\u2013S12. https:\/\/doi.org\/10.12968\/bjon.2014.23.sup16.s4","DOI":"10.12968\/bjon.2014.23.Sup16.S4"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Rugo, H.S., Klein, P., Melin, S.A., Hurvitz, S.A., Melisko, M.E., Moore, A., . . . Cigler, T. (2017). Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA, 317(6), 606\u2013614. https:\/\/doi.org\/10.1001\/jama.2016.21038","DOI":"10.1001\/jama.2016.21038"},{"key":"44","unstructured":"Rugo, H.S., & Melin, S.A. (2013, March 13). Expert statement on scalp cooling with adjuvant\/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases [Paper presented]. St Gallen 13th International Breast Cancer Conference, St Gallen, Switzerland."},{"key":"45","doi-asserted-by":"crossref","unstructured":"Segaert, S., & Van Cutsem, E. (2005). Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Annals of Oncology, 16(9), 1425\u20131433. http:\/\/dx.doi.org\/10.1093\/annonc\/mdi279","DOI":"10.1093\/annonc\/mdi279"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Shacham Shmueli, E., Geva, R., Yarom, N., Hubert, A., Keynan, R., Kedem, T.H., . . . Shirvan, M. (2019). Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: An exploratory phase 2, randomized, double-blind clinical study. Supportive Care in Cancer, 27(8), 3027\u20133033. https:\/\/doi.org\/10.1007\/s00520-018-4600-8","DOI":"10.1007\/s00520-018-4600-8"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Shinohara, A., Ikeda, M., Okuyama, H., Kobayashi, M., Funazaki, H., Mitsunaga, S., . . . Saitoh, S. (2015). Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: A retrospective study. American Journal of Clinical Dermatology, 16(3), 221\u2013229. https:\/\/doi.org\/10.1007\/s40257-015-0116-x","DOI":"10.1007\/s40257-015-0116-x"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Shinohara, N., Nonomura, N., Eto, M., Kimura, G., Minami, H., Tokunaga, S., & Naito, S. (2014). A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. Annals of Oncology, 25(2), 472\u2013476. https:\/\/doi.org\/10.1093\/annonc\/mdt541","DOI":"10.1093\/annonc\/mdt541"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Templeton, A.J., Ribi, K., Surber, C., Sun, H., Hsu Schmitz, S.F., Beyeler, M., . . . Ruhstaller, T. (2014). Prevention of palmar\u2013plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92\/08). Breast, 23(3), 244\u2013249. https:\/\/doi.org\/10.1016\/j.breast.2014.02.005","DOI":"10.1016\/j.breast.2014.02.005"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Toyama, T., Yoshimura, A., Hayashi, T., Kobayashi, N., Saito, K., Tsuneizumi, M., . . . Iwata, H. (2018). A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. Breast Cancer, 25(6), 729\u2013735. https:\/\/doi.org\/10.1007\/s12282-018-0879-z","DOI":"10.1007\/s12282-018-0879-z"},{"key":"51","unstructured":"U.S. Department of Health and Human Services. (2017). Common Terminology for Adverse Events (CTCAE) [version 5.0]. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs..."},{"key":"52","doi-asserted-by":"crossref","unstructured":"van den Hurk, C.J.G., van den Akker-van Marle, M.E., Breed, W.P.M., van de Poll-Franse, L.V., Nortier, J.W.R., & Coebergh, J.W.W. (2013). Impact of scalp cooling on chemotherapy-induced alopecia, wig use and hair growth of patients with cancer. European Journal of Oncology Nursing, 17(5), 536\u2013540. https:\/\/doi.org\/10.1016\/j.ejon.2013.02.004","DOI":"10.1016\/j.ejon.2013.02.004"},{"key":"53","doi-asserted-by":"crossref","unstructured":"van den Hurk, C.J., van den Akker-van Marle, M.E., Breed, W.P., van de Poll-Franse, L.V., Nortier, J.W., & Coebergh, J.W. (2014). Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia. Acta Oncologica, 53(1), 80\u201387. https:\/\/doi.org\/10.3109\/0284186x.2013.794955","DOI":"10.3109\/0284186X.2013.794955"},{"key":"54","doi-asserted-by":"crossref","unstructured":"von Gruenigen, V., Frasure, H., Fusco, N., DeBernardo, R., Eldermire, E., Eaton, S., & Waggoner, S. (2010). A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer, 116(20), 4735\u20134743. https:\/\/doi.org\/10.1002\/cncr.25262","DOI":"10.1002\/cncr.25262"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Wallner, M., K\u00f6ck-H\u00f3di, S., Booze, S., White, K., & Mayer, H. (2016). Nursing management of cutaneous toxicities from epidermal growth factor receptor inhibitors. Clinical Journal of Oncology Nursing, 20(5), 529\u2013536. https:\/\/doi.org\/10.1188\/16.CJON.529-536","DOI":"10.1188\/16.CJON.529-536"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Watanabe, T., Yagata, H., Saito, M., Okada, H., Yajima, T., Tamai, N., . . . Ohashi, Y. (2019). A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients. PLOS ONE, 14(1), e0208118. https:\/\/doi.org\/10.1371\/journal.pone.0208118","DOI":"10.1371\/journal.pone.0208118"},{"key":"57","unstructured":"Wells, G.A., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., & Tugwell, P. (2017). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottowa Hospital Research Institute. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"58","unstructured":"World Health Organization. (1979). WHO handbook for reporting results of cancer treatment. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/37200\/WHO_OFFSET_48.pdf..."},{"key":"59","unstructured":"Yamada, M., Iihara, H., Fujii, H., Ishihara, M., Matsuhashi, N., Takahashi, T., . . . Itoh, Y. (2015). Prophylactic effect of oral minocycline in combination with topical steroid and skin care against panitumumab-induced acneiform rash in metastatic colorectal cancer patients. Anticancer Research, 35(11), 6175\u20136181."},{"key":"60","doi-asserted-by":"crossref","unstructured":"Yap, Y.S., Kwok, L.L., Syn, N., Chay, W.Y., Chia, J.W.K., Tham, C.K., . . . Soong, R.C.T. (2017). Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: A randomized clinical trial. JAMA Oncology, 3(11), 1538\u20131545. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1269","DOI":"10.1001\/jamaoncol.2017.1269"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Ding, Y., Lu, Y., Zhang, J., Gu, J., & Li, M. (2013). Incidence and self-management of hand-foot syndrome in patients with colorectal cancer. Clinical Journal of Oncology Nursing, 17(4), 434\u2013437. https:\/\/doi.org\/10.1188\/13.CJON.434-437","DOI":"10.1188\/13.CJON.434-437"}],"container-title":["Oncology Nursing Forum"],"original-title":[],"link":[{"URL":"http:\/\/onf.ons.org\/onf\/47\/5\/targeted-therapy-and-chemotherapy-associated-skin-toxicities-systematic-review-and-meta","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:04Z","timestamp":1763754604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/onf\/47\/5\/targeted-therapy-and-chemotherapy-associated-skin-toxicities"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1188\/20.onf.e149-e160","relation":{},"ISSN":["0190-535X","1538-0688"],"issn-type":[{"value":"0190-535X","type":"print"},{"value":"1538-0688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}